Rolfo, CHRISTIAN DIEGO
 Distribuzione geografica
Continente #
NA - Nord America 5.005
AS - Asia 1.644
EU - Europa 1.520
SA - Sud America 228
AF - Africa 28
OC - Oceania 3
Totale 8.428
Nazione #
US - Stati Uniti d'America 4.950
SG - Singapore 694
RU - Federazione Russa 475
CN - Cina 408
IT - Italia 296
BR - Brasile 183
HK - Hong Kong 148
VN - Vietnam 136
DE - Germania 121
FI - Finlandia 113
GB - Regno Unito 100
PL - Polonia 96
FR - Francia 72
IE - Irlanda 68
JP - Giappone 47
KR - Corea 43
SE - Svezia 40
CA - Canada 32
BD - Bangladesh 31
IN - India 30
ES - Italia 23
RO - Romania 19
TR - Turchia 18
AR - Argentina 15
AT - Austria 15
BE - Belgio 15
IQ - Iraq 13
UA - Ucraina 13
IR - Iran 11
UZ - Uzbekistan 10
NL - Olanda 9
CH - Svizzera 7
EC - Ecuador 7
MX - Messico 7
AL - Albania 6
ID - Indonesia 6
LB - Libano 6
PY - Paraguay 6
VE - Venezuela 6
CI - Costa d'Avorio 5
GR - Grecia 5
LT - Lituania 5
MA - Marocco 5
MY - Malesia 5
PK - Pakistan 5
ZA - Sudafrica 5
CL - Cile 4
CZ - Repubblica Ceca 4
IL - Israele 4
SV - El Salvador 4
AE - Emirati Arabi Uniti 3
AZ - Azerbaigian 3
JM - Giamaica 3
KE - Kenya 3
NP - Nepal 3
PH - Filippine 3
PT - Portogallo 3
RS - Serbia 3
SA - Arabia Saudita 3
UY - Uruguay 3
AU - Australia 2
BA - Bosnia-Erzegovina 2
CO - Colombia 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
EG - Egitto 2
HR - Croazia 2
KG - Kirghizistan 2
KZ - Kazakistan 2
PE - Perù 2
TH - Thailandia 2
TW - Taiwan 2
BG - Bulgaria 1
BW - Botswana 1
BY - Bielorussia 1
CR - Costa Rica 1
CU - Cuba 1
DK - Danimarca 1
EE - Estonia 1
ET - Etiopia 1
GA - Gabon 1
GE - Georgia 1
GH - Ghana 1
GP - Guadalupe 1
IS - Islanda 1
JO - Giordania 1
KW - Kuwait 1
KY - Cayman, isole 1
LV - Lettonia 1
MC - Monaco 1
NG - Nigeria 1
NI - Nicaragua 1
NZ - Nuova Zelanda 1
PA - Panama 1
PS - Palestinian Territory 1
QA - Qatar 1
SK - Slovacchia (Repubblica Slovacca) 1
SY - Repubblica araba siriana 1
TN - Tunisia 1
TT - Trinidad e Tobago 1
Totale 8.428
Città #
Fairfield 723
Ashburn 565
Singapore 475
Woodbridge 355
Seattle 312
Houston 309
Chandler 307
Cambridge 276
Wilmington 258
San Jose 209
Ann Arbor 167
Hong Kong 143
Moscow 89
Beijing 88
Zgierz 81
Palermo 76
Council Bluffs 74
Medford 67
Dublin 64
Altamura 51
Los Angeles 50
New York 47
Helsinki 46
Santa Clara 46
Tokyo 44
Princeton 42
The Dalles 42
Ho Chi Minh City 41
Nanjing 41
Des Moines 40
Boardman 38
Lauterbourg 38
Lawrence 38
Hanoi 37
Twinsburg 32
San Diego 28
Dearborn 25
London 25
Dallas 24
Frankfurt am Main 23
Panama City 23
Phoenix 23
Chicago 22
Nanchang 19
Ludwigshafen am Rhein 17
Redwood City 17
Rome 17
Shenyang 17
Orem 16
Buffalo 15
Changsha 15
Brussels 14
Tianjin 14
São Paulo 12
Warsaw 12
Da Nang 11
Hebei 11
Jinan 11
Tulsa 11
Guangzhou 10
Jiaxing 10
San Paolo di Civitate 10
Zhengzhou 10
Hefei 9
Milazzo 9
Baghdad 8
Brooklyn 8
Izmir 8
Milan 8
Seongnam 8
Seoul 8
Shanghai 8
Belo Horizonte 7
Denver 7
Falkenstein 7
Madrid 7
Ningbo 7
Tashkent 7
Boston 6
Bremen 6
Chennai 6
Columbus 6
Hangzhou 6
Kitzingen 6
Manchester 6
Tirana 6
Toronto 6
Abidjan 5
Amsterdam 5
Asunción 5
Dhaka 5
Forest City 5
Haiphong 5
Madison 5
Montreal 5
Mumbai 5
Naples 5
Saint Petersburg 5
Vienna 5
Washington 5
Totale 6.008
Nome #
PD-L1 expression as predictive biomarker in patients with NSCLC: A pooled analysis 347
Entrectinib: A potent new TRK, ROS1, and ALK inhibitor 284
HepatomiRNoma: The proposal of a new network of targets for diagnosis, prognosis and therapy in hepatocellular carcinoma 261
Metastatic site location influences the diagnostic accuracy of ctDNA EGFR- mutation testing in NSCLC patients: a pooled analysis 261
New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: Do all roads lead to RAS? 256
Curcumin inhibits in vitro and in vivo chronic myelogenous leukemia cells growth: a possible role for exosomal disposal of miR-21 256
Exosomes in semen: Opportunities as a new tool in prostate cancer diagnosis 255
What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis 250
Farletuzumab for NSCLC: Exploiting a well-known metabolic pathway for a new therapeutic strategy 245
Cancer and the microbiome: Potential applications as new tumor biomarker 244
Adjuvant Chemoradiation Therapy in Gastric Cancer: Critically Reviewing the Past and Visualizing the Next Step Forward 235
Effects of exosomes released by NSCLC cells on osteoclasts differentiation. 232
Exosomes isolation and characterization in serum is feasible in non-small cell lung cancer patients: critical analysis of evidence and potential role in clinical practice 231
The Synergistic Effect of SAHA and Parthenolide in MDA-MB231 Breast Cancer Cells 228
Multisciplinary management of patients with liver metastasis from colorectal cancer 224
Dilemma in metastatic colorectal cancer: VEGF versus EGRF targeting 211
Exosomes as diagnostic and predictive biomarkers in lung cancer 204
Exosomal miRNA analysis in non-small cell lung cancer (NSCLC) patients' plasma through qPCR: A feasible liquid biopsy tool 204
Monoclonal antibodies for the treatment of non-haematological tumours: Update of an expanding scenario 202
Central nervous system involvement in ALK-rearranged NSCLC: promising strategies to overcome crizotinib resistance 197
Targeting angiogenesis in biliary tract cancers: An open option 194
Liquid Biopsy in Non-Small Cell Lung Cancer (NSCLC) 192
In silico pathway analysis in cervical carcinoma reveals potential new targets for treatment 191
Use of the word “cured” for cancer patients—implications for patients and physicians: The Siracusa charter 190
Immune checkpoint inhibitors in lung cancer: the holy grail has not yet been found… 185
Retinoic Acid affects Lung Adenocarcinoma growth by inducing differentiation via GATA6 activation and EGFR and Wnt inhibition 180
EML4-ALK translocation identification in RNA exosomal cargo (ExoALK) in NSCLC patients: a novel role for liquid biopsy 179
Improving extracellular vesicles visualization: From static to motion 179
Role of NSCLC exosomes in osteoclast differentiation 178
BRAF mutations in non-small cell lung cancer: Has finally Janus opened the door? 172
ALK and crizotinib: After the honeymoon...what else? Resistance mechanisms and new therapies to overcome it 167
The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet? 164
Molecular profiling of pancreatic neuroendocrine tumors (pNETS) and the clinical potential 157
Curcumin induces selective packaging of miR-21 in exosomes released by Chronic Myelogenous Leukemia cells 153
The role of cMET in non-small cell lung cancer resistant to EGFR-Inhibitors: Did we really find the target? 152
Second-Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological, and Molecular Aspects of Nintedanib 150
VIPoma and PPoma 144
The diagnostic accuracy of PIK3CA mutations by circulating tumor DNA in breast cancer: an individual patient data meta-analysis 143
Upfront radiation versus EGFR-TKI: Which is the best approach for EGFR-mutated NSCLC patients with brain metastasis? 143
Corrigendum to "Liquid biopsies in lung cancer: The new ambrosia of researchers" [Biochem. Biophys. Act. 1846(2014) 539-546] 143
Ramucirumab and its use in gastric cancer treatment 140
Indications for locoregional tumor therapies: CRC liver metastases 118
The prognostic impact of tumor mutational burden (TMB) in the first-line management of advanced non-oncogene addicted non-small-cell lung cancer (NSCLC): a systematic review and meta-analysis of randomized controlled trials 108
Liquid biopsy: a right tool in a right context? 75
Human papillomavirus infection and lung adenocarcinoma: special benefit is observed in patients treated with immune checkpoint inhibitors 48
Abstract 2055: Isoform-aware miRNA network mapping in NSCLC via computational consensus targeting and functional clustering 26
null 16
Totale 8.714
Categoria #
all - tutte 30.730
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 30.730


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022574 31 107 30 20 19 27 20 45 61 81 45 88
2022/2023811 73 168 36 112 83 122 29 61 66 3 39 19
2023/2024363 14 48 26 26 19 56 63 23 18 11 3 56
2024/2025848 11 69 81 71 37 34 40 76 49 79 130 171
2025/20262.703 226 85 146 179 308 379 394 335 228 207 92 124
2026/202791 91 0 0 0 0 0 0 0 0 0 0 0
Totale 8.714